Introduction: Incidence of type 2 diabetes (T2DM) among young adults has been increasing rapidly. We have noticed a significant increase in consultations received for patients with T2DM diagnosed at age <40 and much younger ages. Patients diagnosed at younger age are at higher risk of microvascular and macrovascular complications over their lifetime. We aim to characterize the clinical characteristics of this patient population.
Methods: All patients (new and follow-up) with T2DM and age≤ 50 years, at our Diabetes and Endocrinology Centre were included. 95 patients (21% of all patients in our diabetes registry) met the eligibility criteria. Demographic variables. comorbidities, diabetes complications, vitals, lab parameters and medications were reviewed.
Results: n=38 (40%) were females. Sixty-eight (71%) were South Asians. Mean age at diagnosis was 34 years(± 7.2). Normal, overweight and obese BMI was seen in 25%, 42% and 33% of South Asians and 12%, 25% and 62% of Caucasians, respectively. South Asians were diagnosed at a younger age with 9%, 16% and 57% diagnosed at age <20, 21-30 and 31-40, respectively, compared to Caucasians 0%, 12.5% and 50% for the same age distribution above. Prevalence of dyslipidemia (86%), Hypertension (62%), retinopathy (4%), neuropathy (21%), nephropathy (29%), CAD (4%), stroke 2% and PVD was 0%, reflecting the younger population in this study.
Conclusion: A large proportion of patients in our diabetes registry are young or middle aged. South Asian ethnicity increases risk of diabetes at a younger age and lower BMI. The epidemic of diabetes at a young age is likely related to increased sedentary lifestyle, inadequate sleep, stress and increasing use of technology and screens.
K. Suntharamoorthy: None. S. Dave: None. U. Muhammad: None. E. Javaid: None. N. Gupta: Consultant; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk Inc., Sanofi.